|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Aida Pharmaceuticals Inc., of Hangzhou, China, agreed to purchase the remaining outstanding shares of Shanghai Qiaer Bio-Technology Co. Ltd. that it does not already own from Zhejiang Pharmaceutical Co. Ltd. Under the terms, Aida will buy an additional 45 percent of the outstanding shares for $495,650, adding to the previous payment of $561,324 as a deposit to purchase 55 percent of Shanghai's shares. Shanghai will become a wholly owned subsidiary of Aida. The transaction is expected to close at the end of June. Shanghai's key product is rh-Apo21, a gene therapy drug used to treat certain forms of cancer, which is nearing the end of Phase I trials.
o American ...
Related newspaper, magazine, and journal articles:
|
|
Article: MEGABIOS, GENEMEDICINE AGREE TO `STRATEGIC MERGER' THAT POOLS ...
BIOWORLD Today;
October 27, 1998 ;
700+ words
... ... percent, or $0.281. McGraw told BioWorld Today the move is one of the few "strategic ... into GeneMedicine," Weintraub told BioWorld Today. "This merger allows us to simplify ... up relatively early," Waldron told BioWorld Today. "This merger announcement is the ...
|
|